Retatrutide and the GLP-1 research peptide class

Few research peptides have drawn as much interest as the GLP-1 / incretin class. This guide outlines what Retatrutide is, how it relates to the better-known members of the class, and the receptor pathways it is studied for in laboratory settings. Everything here is research context only.

What is Retatrutide?

Retatrutide is a synthetic triple-agonist peptide investigated in research as a GLP-1, GIP and glucagon receptor agonist. That three-receptor profile is what distinguishes it from earlier single- and dual-agonist research compounds, and it is studied in experimental models of incretin signalling and metabolic regulation.

The wider incretin research class

The GLP-1 receptor agonist class is the same family that includes the widely-studied semaglutide and the dual GLP-1/GIP agonist tirzepatide. A complementary research compound is Cagrilintide, a long-acting amylin receptor agonist studied for amylin-receptor signalling rather than the incretin receptors directly. Researchers comparing these compounds are typically looking at receptor selectivity, half-life and signalling-pathway differences in vitro.

Mitochondrial-derived peptides: a different mechanism

Not every metabolic-research peptide acts on incretin receptors. MOTS-C is a mitochondrial-derived peptide studied for AMPK-pathway signalling and metabolic homeostasis, a distinct mechanism that is often examined alongside the receptor agonists above.

Research use only

All compounds discussed here are supplied strictly for laboratory and in-vitro research, not for human or veterinary use. Every Kovalabs batch is third-party tested with a certificate of analysis. See the full research disclaimer for terms.